Among patients with PsA, MetS is associated with certain degenerative changes in the spine and entheses but not with peripheral or axial radiographic damage.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Originally ...

Having psoriasis raises your risk of psoriatic arthritis — and rheumatoid arthritis, too. Make sure you can tell these two forms of arthritis apart.

Psoriatic arthritis represents a complex interplay between two distinct conditions. For most people, the skin symptoms appear first—typically red, scaly patches known as plaques that can appear ...

Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures. Babies and ...

Adam also apologised to his followers for having not been "very vocal" about his experience with arthritis lately. He told them in the recent post on Instagram: "[I'm] just struggling and trying ...

Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

Johnson & Johnson announced that the Tremfya (guselkumab) phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing ...

"J&J’s psoriatic arthritis therapy trial meets endpoints" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included ...

This autoimmune disorder manifests through various symptoms that can significantly ... those genetically susceptible. The clinical presentation of psoriatic arthritis varies dramatically across ...

for active psoriatic arthritis (PsA). The APEX trial met both its primary and major secondary endpoints at 24 weeks in adults with active PsA. The double-blind, multi-centre trial showed that the ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...